Presbyopia

Phentolamine Ophthalmic Solution 0.75% is a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, administered as an eye drop for the treatment of presbyopia.

The FDA has set a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026.

Alex Hacopian, MD, highlights how a recent ambispective study demonstrated strong visual acuity outcomes and patient satisfaction following bilateral implantation of an advanced presbyopia-correcting intraocular lens.

Updated guidelines characterize IOLs by functional performance over optical design.

Personalizing treatment options and setting realistic expectations are crucial.

BRIMOCHOL PF’s combination of brimonidine and carbachol produces a “pinhole effect,” which is intended to improve depth of focus and sharpen near and distant impact.

The novel corrective eye drop can be prescribed through pharmacy partners BlinkRx or Medvantx

Kearney will lead Tenpoint’s commercial strategy, including preparation of the potential US launch of BRIMOCHOL PF.

Patients’ near visual needs is important when prescribing medications for glaucoma treatment

The clinical trial successfully met pre-specified visual acuity primary endpoints in both the US and European Union (EU)/United Kingdom (UK) with statistically significant near vision improvements recorded at all time points over 8 hours

Research was based on results of a double-blinded, randomized, clinical trial performed between November 2017 and December 2022 in the strabismus clinic of Farabi Eye Hospital.

74% of participants dosed with LNZ100 achieved 3 or more lines of improvement 3 hours post-treatment.

According to the company, a $68 million Series D financing is co-led by Arboretum Ventures and Johnson & Johnson Innovation – JJDC Inc. It also has secured $15 million in structured capital from Catalio Capital Management, with $10 million drawn at closing.

The trial is evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia.

Explore cutting-edge ophthalmology innovations in this new series on the Ophthalmology Times EyePod podcast. Throughout this series, we'll hear insights from various stakeholders in clinical practice, academia, and industry. In this episode, host Ehsan Sadri, MD, engages in a conversation with Jeffry Weinhuff, managing partner at Visionary Ventures, exploring trends and offering advice for individuals driven by an entrepreneurial mindset.

Infuse Multifocal silicone hydrogel (SiHy) daily disposable contact lenses leverage Bausch + Lomb’s proprietary lens tech to deliver all-day comfort and seamless transitions between near, intermediate, and distance vision for patients with presbyopia.

Preeya Gupta, MD, reported results of the trials at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, showed that CSF-1, a low dose pilocarpine with an optimized formulation, demonstrated significant 2-line improvement from baseline.

Allergan developed VUITY, which it noted is the first and only FDA-approved eye drop to treat presbyopia. The FDA has now approved a two-dose option.

Ehsan Sadri, MD, FACS, and William Trattler, MD, highlight some of the pending FDA approvals and PDUFA dates in the anterior segment sector and what these products will mean for ophthalmologists and their patients.

BRIO-I is a double-masked, randomized, multi-center, safety and efficacy study that enrolled emmetropic phakic and pseudophakic presbyopic subjects.

According to the company, the investigational, novel eye drop candidate was assigned a PDUFA goal date of October 22, 2023.

According to Lento Bio, its collaboration with FSU will focus on medicinal chemistry and will help accelerate lead asset development, with board expansion focused on well-rounded scientific expertise.

According to the company, the launch of the presbyopia phase 3 program is supported by positive clinical results that demonstrated durable efficacy and a favorable safety profile.

Investigators test the efficacy of phentolamine alone and with low-dose pilocarpine.

Francis S. Mah, MD, and Andrew S. Morgenstern, OD, FAAO, FNAP, review the impact of presbyopia on quality of life as well as current treatment options and unmet needs for disease management.